Exploring the Rapidly Evolving Landscape of Options to Treat Cervical Cancer

Statement of Need

Recent advances in the treatment of gynecologic cancers are promising, and education is needed to ensure that both oncology and primary care clinicians, including OB/GYNs, have a thorough knowledge of the latest clinical trial data and its translation to real-world practice. In particular, recently approved therapeutic options for the treatment of cervical cancer necessitate an understanding of these options in order to choose the best treatment options for patients with cervical cancer. Members of the multidisciplinary team tasked with care for patients with cervical cancer need to know about the efficacy and safety data of these potential therapy options to be able to determine the value of each for those recently diagnosed or living with recurrent cervical cancer.

In the sixth activity of this CME Outfitters podcast series on gynecologic cancers, expert faculty will present and discuss the very latest research on treatment options for cervical cancer, including recently approved treatments, and how to choose between them for patients with recurrent cervical cancer.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

Differentiate the efficacy and safety data of recently approved therapeutic options for the treatment of cervical cancer

Financial Support

Supported by independent educational grants from AstraZeneca Pharmaceuticals and Merck & Co., Inc., Rahway, NJ, USA.

Target Audience

Gynecologic oncologists, medical oncologists, gynecologists, physician associates (PAs), nurses, nurse practitioners (NPs), and pharmacists

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME) 0.5

CME Outfitters, LLC, designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists (ACPE) 0.5

This application-based activity is approved for 0.50 contact hours (0.05 CEUs) of continuing pharmacy credit (JA0007185-0000-25-025-H01-P).

Nurses (ANCC) 0.5

This activity is designated for 0.50 contact hours.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.

Interprofessional (IPCE) 0.5

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education Credit for learning and change.

Physician Assistants (AAPA): 0.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until 01/31/2026. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 0.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. Relevant financial relationships exist between the following individuals and commercial interests:

Dr. Penson reports the following financial relationships:

Advisory Board: Aadi Bioscience; AstraZeneca; GSK; ImmunoGen, Inc.; Merck & Co., Inc.; Mersana Therapeutics; Novacure; Roche; Sutro Biopharma, Inc.; and Vascular Biogenics

Consultant: Serves on DSMBs for AstraZeneca; EQRx; and Roche

Other financial or material support: Royalties: BMJ Publishing Group Ltd; Elsevier; UpToDate, Inc.; Wolters Kluwer Health and Wiley-Blackwell. Payment for educational events: Research to Practice; ExpertConnect; and ReachMD, and CME Outfitters

Dr. Monk reports the following financial relationships:

Consultant: Acrivon Therapeutics; Adaptimmune; Amgen Inc.; AstraZeneca; Biohaven, Ltd; BioNTech SE; Bristol Myers Squibb Company; Corcept Therapeutics; Eisai Inc.; Lilly; Genmab/Seagen Inc./Pfizer Inc.; Genelux Corporation; GOG Foundation Inc.; Gradalis, Inc.; GSK; Hengrui; ImmunoGen, Inc./AbbVie Inc.; Karyopharm; Iovance Biotherapeutics, Inc.; Merck & Co., Inc.; Mersana Therapeutics; Mursla Inc./Alkermes; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Novocure; OncoC4; Panavance Therapeutics Inc.; ProfoundBio; Regenron Pharmaceuticals Inc./Genmab; Roche/Genetech, Inc.; Sutro Biopharma, Inc.; Verastem, Inc.; Zentalis Pharmaceuticals; and Zymeworks Inc.

Speakers Bureau: AstraZeneca; Eisai Inc.; GSK; ImmunoGen, Inc./AbbVie Inc.; and Merck & Co., Inc.

The following individuals have no financial relationships to disclose:

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Michael Franks, APRN, AGACNP-BC, FNP-BC (Peer Reviewer)
Mary Gleason, PhD, CHCP (Planning Committee)
David Modrak, PhD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

PD-112-013125-90